TABLE 1.
Patient Characteristics
| Characteristic | Median or number | Range |
| Age (y) | 71 | 50–87 |
| Time since diagnosis of prostate cancer (y) | 8 | 2–17 |
| Gleason score | 8 | 6–10 |
| Alkaline phosphatase (U/L) | 131 | 49−1,896 |
| Hemoglobin (g/L) | 117 | 88–151 |
| Lactate dehydrogenase (U/L) | 268 | 148–1,331 |
| PSA (ng/mL) | 189.8 | 7–4,022 |
| PSA doubling time (mo) | 2.3 | −5.8 to 22.9 |
| Eastern Cooperative Oncology Group performance status | ||
| 0 | 20 (40%) | |
| 1 | 22 (44%) | |
| 2 | 8 (16%) | |
| Prior therapies | ||
| Abiraterone or enzalutamide or both | 46 (92%) | |
| Docetaxel | 42 (84%) | |
| Cabazitaxel | 24 (48%) | |
| Docetaxel + enzalutamide/abiraterone ± cabazitaxel | 39 (78%) | |
| Stage of disease (68Ga-PSMA-11 PET) | ||
| Node only (M1a) | 2 (4%) | |
| Bone (M1b) | 38 (76%) | |
| Visceral (M1c) | 10 (20%) | |
| Pain at baseline (BPI pain severity score) | ||
| None (<1) | 8 (16%) | |
| Mild (1–4) | 29 (58%) | |
| Moderate to severe (5–10) | 13 (26%) |